Maravai LifeSciences (MRVI) Projected to Post Earnings on Wednesday

Maravai LifeSciences (NASDAQ:MRVI) is expected to be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect Maravai LifeSciences to post earnings of ($0.0563) per share and revenue of $43.56 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.02. Maravai LifeSciences had a negative net margin of 37.07% and a negative return on equity of 15.70%. The business had revenue of $51.44 million during the quarter, compared to the consensus estimate of $48.67 million. On average, analysts expect Maravai LifeSciences to post ($0.18) EPS for the current fiscal year and ($0.13) EPS for the next fiscal year.

Maravai LifeSciences Trading Up 5.0%

NASDAQ MRVI opened at $7.55 on Tuesday. The firm’s 50 day moving average price is $7.47 and its two-hundred day moving average price is $5.25. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.98 and a current ratio of 4.05. Maravai LifeSciences has a twelve month low of $2.55 and a twelve month high of $9.42. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -14.42 and a beta of 0.54.

Wall Street Analysts Forecast Growth

MRVI has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Wednesday, August 26th. UBS Group upped their target price on Maravai LifeSciences from $2.50 to $8.00 and gave the company a “neutral” rating in a report on Wednesday, September 9th. Wells Fargo & Company increased their price target on shares of Maravai LifeSciences from $5.50 to $6.50 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Wall Street Zen cut shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a report on Saturday, August 29th. Finally, TD Cowen began coverage on shares of Maravai LifeSciences in a research report on Monday, October 5th. They set a “buy” rating and a $9.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Maravai LifeSciences has an average rating of “Moderate Buy” and a consensus price target of $7.38.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc is a life sciences company that provides products and services used in the development, manufacture and quality testing of biopharmaceuticals, vaccines and diagnostic products. The company serves pharmaceutical, biotechnology, academic and other research organizations involved in nucleic acid and biologics development.

Through its TriLink BioTechnologies business, Maravai supplies specialized nucleic acid products and services, including modified nucleotides, messenger RNA-related materials, enzymes and other components used in research and biomanufacturing.